 "'Optimistic' about Trump administration, says drugmaker Dr Reddy's")
Indian generic drugmaker Dr Reddy's Laboratories on Thursday said it was optimistic about the Donald Trump administration, as it believes the country would have an edge amid tensions between the United States and China.
"I believe that the type of products that we bring in and the positioning of India is favorable," CEO Erez Israeli said in a press call, adding that the company's drugs in the U.S. market are cheaper than the current alternatives.
"..This is very much what also I believe the U.S. administration wants," he said.
Earlier in the day, the generic drugmaker reported consolidated net profit of Rs 1,414 crore ($163.7 million) for the quarter ended Dec. 31, missing analysts' estimate of Rs 1,489 crore as per data compiled by LSEG.
Indian generic drugmakers have been struggling with sales slowdown in the U.S., delayed approvals for new drug applications, and lower pricing amid stiff competition, according to analysts.
Also Read
Revenue from North America, Dr Reddy's biggest geography, rose 1 per cent to 33.80 billion rupees, as volume growth on the back of new launches was offset by lower prices.
"The sequential decline was largely on account of lower sales of certain products including Lenalidomide," the company said.
Lenalidomide, a major contributor to Dr Reddy's North America sales since 2022, is a generic version of Bristol-Myers Squibb's popular cancer treatment drug Revlimid.
Still, Reddy's total revenue climbed 16 per cent to Rs 8,381 crore, beating analysts' estimate, boosted by a 14 per cent growth in its India sales.
The growth was also aided by revenue from the company's in-licensed vaccine portfolio. Last year, Reddy's partnered with French drugmaker Sanofi for distribution of its vaccines in India.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)